查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1832351

乳癌液態切片市場（按技術、生物標記類型、應用、樣本類型、最終用戶和癌症分期）—2025-2032 年全球預測

Breast Cancer Liquid Biopsy Market by Technology, Biomarker Type, Application, Sample Type, End User, Cancer Stage - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年乳癌液態切片市場規模將成長至 25.3499 億美元，複合年成長率為 19.99%。

主要市場統計數據
基準年2024年 5.8992億美元
預計2025年 7.0585億美元
預測年份：2032年 2,534,990,000美元
複合年成長率（%） 19.99%

闡明影響當代乳癌液態切片活體組織切片應用和策略重點的技術、臨床和商業動態的方向

乳癌液態切片已從前景光明的調查工具發展成為日益實用的傳統診斷輔助手段，為腫瘤生物學研究提供了一個微創的窗口。本概述整合了當代科學進展、臨床應用模式和商業性動態，為領導者提供簡潔可行的指導。液態切片所依賴的技術套件種類繁多，包括高靈敏度的分子檢測和廣泛的基因組分析方法，以滿足從早期檢測到復發監測的特定臨床需求。

近期的臨床研究和監管里程碑凸顯了液態切片的價值：識別治療方法選擇中可行的改進措施，監測微量殘存疾病以確定是否停止治療或增加劑量，以及製定監測策略以減少對侵入性組織取樣的依賴。同時，樣本處理、檢測標準化和資訊學方面的創新提高了不同實驗室之間結果的可重複性和可解釋性。因此，診斷、臨床護理和生命科學投資領域的相關人員必須將快速的技術進步與報銷、實驗室工作流程和臨床醫生的採用等現實情況相協調。

有鑑於此，執行摘要關注影響相關人員選擇的最重要的轉變。它強調了對產品開發、臨床檢驗、監管策略和商業模式的實際影響，並指出了近期出現的差異化機會。目標是幫助決策者專注於了解決定液態切片生態系統成功的技術發展軌跡和營運槓桿。

技術進步、多模態生物標記和不斷發展的臨床工作流程的融合如何迅速重塑乳癌液態切片的實踐和商業化

由於技術日趨成熟、臨床證據不斷累積以及醫療模式向微創診斷方法轉變，乳癌液態切片的前景正在改變。檢測靈敏度的提高擴大了臨床應用範圍，使得檢測出先前低於可靠閾值的低頻突變和微小殘留疾病訊號成為可能。這些技術進步為新的臨床應用打開了大門，包括復發的縱向監測、晚期和早期疾病的分子引導治療選擇，以及針對高風險族群的標標靶化篩檢策略。

同時，多分析物方法和更豐富的生物標記組合的整合，正在推動從單一分析物檢測到結合循環腫瘤DNA訊號、循環性腫瘤細胞、外泌體內容物和蛋白質標記的平台轉變。正交分析物的整合正在提高臨床解讀的可靠性，並減少篩檢的假陽性。同時，生物資訊學的日益複雜化，包括機器學習主導的訊號反捲積和標準化變異註釋，正在減少實驗室間的差異，並提高臨床效用。

監管和報銷生態系統也在發生變化，付款人和指南委員會已經認知到液態切片可以顯著改變患者管理的明確用例。診斷開發人員和臨床網路之間的合作正在加速前瞻性檢驗和真實世界證據的產生。綜合這些因素，商業性成功不僅取決於檢測性能，還取決於生態系統的契合度——實驗室整合、臨床醫生工作流程的協調以及明確的臨床效用證據。

評估近期關稅變化和貿易政策調整如何改變液態切片生態系統的供應鏈、籌資策略和營運成本

制定關稅政策和跨境貿易措施可能會對支持液態切片解決方案的試劑、設備和組件的供應鏈造成巨大壓力。 2025年，關稅調整和貿易相關政策變化將影響進口設備、用於核酸提取和文庫製備的耗材以及專用塑膠和微流體組件的成本。這些進口成本的增加將產生連鎖效應：實驗室營運預算面臨每次檢測試劑成本的增加，儀器供應商和服務供應商必須重新評估銷售定價，採購團隊也必須重新審視籌資策略以保護利潤。

除了直接成本影響外，關稅還可能影響策略採購決策，刺激某些製造活動的近岸外包和供應鏈多元化。雖然垂直整合的製造商和擁有區域生產基地的公司能夠很好地緩衝關稅波動，但依賴專業海外供應商的規模較小、創新企業可能面臨更長的交貨時間和壓縮的利潤率。為此，各公司正在重新協商供應商契約，增加前置作業時間緩衝，並尋求替代材料和最佳化工作流程，以保持其檢測的成本效益。

重要的是，臨床應用和政策相關人員正密切關注成本驅動的檢測可得性變化。實驗室和醫療保健提供者正在考慮在昂貴的高度自動化平台和低成本的手動工作流程之間進行權衡，尤其是在資金緊張的醫療保健系統中。因此，由關稅主導的成本動態正在塑造近期的競爭定位，並促使採購、定價和製造部門採取策略性應對措施。

透過詳細的細分分析，將技術類型、生物標記類別、臨床應用、樣本矩陣、最終用戶概況和癌症階段聯繫起來，確定開發路徑的優先順序

對細分市場的細緻理解，揭示了不同的技術路徑和臨床應用如何創造多種價值路徑。技術細分涵蓋BEAMing、數位PCR、新一代定序和qPCR平台。數位PCR有晶片式和液滴式兩種形式，每種形式都針對不同的通量和靈敏度進行了最佳化。次世代定序儀方法包括專注於可操作熱點的靶向panel、擴展轉錄區覆蓋範圍以實現發現和廣泛分析的全EXOME顯子組測序，以及資源密集度更高但能夠進行全面基因組分析的全基因組測序。定量PCR平台包括用於同時進行標靶檢測的多重定量PCR和用於動態監測應用的即時定量PCR。

生物標記類型的細分涵蓋循環遊離DNA、循環性腫瘤細胞、循環腫瘤DNA和外泌體，其中外泌體分析分為外泌體蛋白和外泌體RNA評估。循環腫瘤DNA和外泌體RNA對於突變分析和非侵入性分子特徵具有重要價值，而循環性腫瘤細胞則提供有助於分析表現型和抗藥性機制的細胞背景資訊。應用主導的細分區分早期檢測、微小殘留疾病、復發監測和治療選擇。早期檢測本身分為高風險篩檢和人群篩檢，而微小殘留疾病則著重於治療後監測，需要極高的敏感度和縱向採樣保真度。

血清、唾液和尿液樣本採集支持分散式採集和以患者為中心的工作流程。最終使用者（診斷實驗室、醫院和研究機構）的營運優先順序、監管能力和採購行為決定了其偏好的吞吐量和報告格式。最後，癌症分期通常分為晚期和早期，晚期通常側重於轉移性疾病的應用，其中組織基因分型和治療決策支持之間的一致性至關重要。綜合考慮這些維度，可以根據特定的臨床路徑和用戶需求客製化產品開發和商業化策略，從而最大限度地提高臨床影響力和應用率。

不同地區的法規環境、付款人行為和臨床網路如何影響液態切片解決方案的採用路徑和策略重點

區域動態正在塑造採用曲線和投資重點，從而在關鍵區域打造差異化的擴展路徑。美洲地區的特點是：強大的臨床研究活動、成熟的伴隨診斷報銷途徑，以及密集的學術醫療中心網路，能夠快速進行前瞻性檢驗。因此，強調臨床效用研究、付款人參與以及與大型實驗室網路合作的商業策略在該地區尤其有效。

歐洲、中東和非洲是一個多元化的地區，其監管環境和國家醫療保健體系各不相同，這些因素影響採購決策。在多個歐洲司法管轄區，對臨床效用和成本效益的深入評估正在影響技術的應用，鼓勵開發者產生真實世界證據和健康經濟數據。同時，該地區的一些市場正在投資擴展數位病理學和分子診斷能力，為能夠提供適應不同報銷系統和檢測基礎設施的整合解決方案的診斷提供者創造了機會。

亞太地區在某些市場展現出快速的臨床應用、政府主導的篩檢和早期檢測計劃以及不斷成長的本地製造能力。該地區的一些政策制定者和醫療保健系統正在積極實施可能納入非侵入性篩檢模式的人口健康計劃。因此，制定兼顧可擴展性、可負擔性以及與當地法規相符的策略，對於在各種醫療保健服務模式中實現更廣泛的應用至關重要。

競爭格局洞察凸顯了平台創新、證據夥伴關係和服務模式如何決定液態切片領域的領導地位

液態切片領域的競爭是平台創新、策略夥伴關係和生態系統編配的結合。成熟的診斷公司和定序專家持續提升檢測靈敏度並拓展可操作性內容，而敏捷的生物技術新興企業則專注於利基臨床應用和獨特的生物標記，以提供差異化優勢。技術提供者和臨床網路之間的合作透過加速前瞻性檢驗研究並將證據產生與臨床決策點相結合，支持路徑的採用。

儀器和耗材製造商正在推行模組化方法，使實驗室能夠在保持分析性能的同時逐步擴大產能。同時，以服務為導向的經營模式——集中式參考檢測、訂閱式分析和實驗室即服務——正日益受到青睞，旨在降低臨床應用門檻並加快獲得結果。投資模式體現了平台主導投資與特定應用型偵測之間的平衡。投資組合多元化可以降低單一用例結果的風險，並增強收益韌性。

此外，整合了強巨量資料分析、標準化報告和臨床醫生解讀支援工具的公司，更有機會在醫院和大型診斷實驗室中獲得採用。與合約研究組織和學術中心建立策略聯盟，有助於進行轉化研究，檢驗臨床效用並促進指南的採用。領先企業將卓越的技術與實用的上市模式和循證夥伴關係關係相結合。

為液體活體組織切片領域的領導者提供液態切片的優先策略行動，以提高檢測性能、穩定供應鏈、確保報銷並加速臨床應用

產業領導者應優先考慮一系列策略行動，以協調科學研究能力、營運可擴展性和付款人準備度。首先，重點是投資於符合特定臨床用例的檢測靈敏度和特異性，特別是那些分析性能直接影響臨床決策的用例，例如微小殘留疾病和高風險族群的早期檢測。將前瞻性臨床試驗融入治療路徑，以補充技術開發，證明對治療選擇和患者預後有實際的影響。

其次，我們將透過多元化零件採購和評估本地製造和組裝方案來增強供應鏈的韌性。這些措施將減少貿易相關成本波動所帶來的風險，並縮短臨床實驗室的部署時間。第三，我們將設計反映最終使用者工作流程的商業模式。這些模式包括為診斷實驗室提供靈活的實驗室整合，為醫院系統提供承包解決方案，以及建立研究夥伴關係，以降低學術中心採用的技術門檻。我們將投資於臨床醫生的解讀工具和報告標準，以減輕認知負擔並簡化部署。

第四，我們正在與付款方和衛生技術評估機構建立早期合作關係，以整合可靠的真實世界證據和符合區域報銷框架的衛生經濟數據。第五，我們正在尋求跨診斷、製藥和臨床研究生態系統的夥伴關係，將檢測方法納入治療開發項目和指南制定研究。最後，我們堅持嚴謹的投資組合策略，在平台投資和標靶檢測方法之間取得平衡，從而既能提供廣泛的能力，又能在重點臨床領域實現差異化。

透明的研究框架，結合系統性的文獻綜述和相關人員訪談，提供檢驗的、基於本地的策略見解

本分析所採用的研究途徑將結構化的二手文獻整合與主要相關人員訪談相結合，以確保研究結果反映當前的科學、監管和商業性現狀。二手文獻研究包括對同行評審的臨床研究、監管指南文件、會議論文集和開放原始碼技術白皮書的系統綜述，以及對檢測性能特徵、生物標記檢驗和不斷發展的臨床指南的分析。已發表的分析靈敏度和特異性基準進行了交叉檢驗，重點是理解當代生物資訊學在變異調用和解讀方面的實踐。

初步研究包括對臨床腫瘤學家、實驗室主任、付款方和行業高管的深入訪談，旨在識別應用障礙、採購重點和證據預期。訪談樣本來自不同地區，旨在捕捉監管解讀和醫療服務提供模式的地區差異。數據和見解透過跨資訊來源三角測量，以減輕單一資訊來源的偏見，並協調對照研究結果與實際營運限制之間的差異。

我們的分析方法包括定性主題分析（旨在提取策略意義）和情境評估（旨在評估政策變化下的供應鏈和定價敏感度）。我們承認研究有其限制；因此，建議持續監測已發表的科學文獻和監管動態。在整個研究過程中，我們遵守倫理研究規範，包括知情同意和專有資訊保密。

關於協調分析創新、證據生成和商業性實施以實現液態切片在乳癌治療中的臨床前景的總結性觀點

乳癌液態切片正處於曲折點，技術能力、臨床需求和商業性獎勵正在相互協調，以實現更廣泛的臨床效用。高靈敏度檢測和多參數方法的成熟，使得非侵入性檢測在治療選擇、微量殘存疾病監測和分層篩檢策略中發揮重要作用成為可能。同時，供應鏈可靠性、報銷協調和實驗室營運整合等實際限制因素將決定其應用的速度和規模。

為了抓住這一機遇，各機構必須採取整合策略，將強大的分析能力與符合臨床決策點和付款人期望的證據生成相結合。在臨床醫生教育、報告標準化以及將檢測方法納入治療開發項目的夥伴關係方面的投資，將加速該技術的採用。由於法律規範、報銷機制和醫療保健服務模式等區域差異，需要採取針對特定地區的方案，而非一刀切的商業化計劃。

最終，液態切片的臨床前景將透過協調一致的行動得以實現：審慎的技術開發、可控的證據生成，以及適應不斷變化的政策和醫療服務環境的商業策略。迅速採取行動協調這些要素的相關人員將最有能力塑造醫療標準，並獲得長期的臨床和商業性價值。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 超靈敏甲基化 ctDNA 檢測的進展提高了乳癌微量殘存疾病的檢測率
  • 擴大照護現場液態生物檢體平台，快速監測轉移性乳癌的治療反應
  • 製藥和診斷公司合作開發用於標靶治療的伴隨液態生物檢體測試
  • 基於外泌體的液態生物檢體測試的出現提供了全面的生物標記分析和對抗藥性的洞察
  • 突破性乳癌液態切片檢測獲得FDA核准監管批准，加速其商業性應用
  • 開發標準化的預分析工作流程，以減少樣本採集和 ctDNA 分析的差異
  • 擴大報銷範圍和支持在臨床實踐中常規使用液態生物檢體的衛生經濟證據
  • 透過整合ctDNA、外泌體RNA和蛋白質標記物的多組體學方法進行全面的疾病監測

第6章 2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章乳癌液態切片市場（按技術）

  • 喜氣洋洋
  • 數位PCR
    • 基於晶片的數位PCR
    • 液滴式數位PCR
  • 下一代定序
    • 目標序列
    • 全EXOME定序
    • 全基因組序列分析
  • 定量PCR
    • 多重定量PCR
    • 即時定量PCR

第9章乳癌液態切片市場（按生物標記類型）

  • 循環遊離DNA
  • 循環性腫瘤細胞
  • 循環腫瘤DNA
  • 外泌體
    • 外泌體蛋白
    • 外泌體RNA

第 10 章乳癌液態切片市場（按應用）

  • 早期檢測
    • 高風險篩檢
    • 人口篩檢
  • 微量殘存疾病
    • 治療後監測
  • 復發監測
  • 治療方案

第 11 章乳癌液態切片市場（依樣本類型）

  • 電漿
  • 唾液
  • 血清
  • 尿

第 12 章乳癌液態切片市場（按最終用戶）

  • 診斷實驗室
  • 醫院
  • 研究所

第13章乳癌液態切片市場（按癌症分期）

  • 晚期
    • 轉移性疾病
  • 早期的

第14章乳癌液態切片市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 15 章乳癌液態切片市場：按類別

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章乳癌液態切片市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Roche Diagnostics International AG
    • Guardant Health, Inc.
    • Natera, Inc.
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • Exact Sciences Corporation
    • Sysmex Inostics GmbH
    • Qiagen NV
    • Bio-Rad Laboratories, Inc.
    • Biocept, Inc.
Product Code: MRR-437D45958552

The Breast Cancer Liquid Biopsy Market is projected to grow by USD 2,534.99 million at a CAGR of 19.99% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 589.92 million
Estimated Year [2025] USD 705.85 million
Forecast Year [2032] USD 2,534.99 million
CAGR (%) 19.99%

A clear orientation to the technological, clinical, and commercial dynamics that define contemporary breast cancer liquid biopsy adoption and strategic priorities

Liquid biopsy for breast cancer has evolved from a promising research tool into an increasingly practical adjunct to conventional diagnostics, offering a minimally invasive window into tumor biology. This summary synthesizes contemporary scientific advances, clinical adoption patterns, and commercial dynamics to provide leaders with a concise, actionable orientation. The technology suite underpinning liquid biopsy is diverse, spanning highly sensitive molecular assays and broad genomic profiling approaches that address distinct clinical needs from early detection to recurrence monitoring.

Recent clinical studies and regulatory milestones have clarified where liquid biopsy adds value: in identifying actionable alterations for therapy selection, monitoring minimal residual disease to support treatment de-escalation or escalation decisions, and enabling surveillance strategies that reduce reliance on more invasive tissue sampling. Simultaneously, innovation in sample handling, assay standardization, and informatics has improved reproducibility and interpretability of results across laboratories. As a result, stakeholders across diagnostics, clinical care, and life sciences investment must reconcile rapid technical progress with the realities of reimbursement, laboratory workflows, and clinician adoption.

Given this context, the executive summary foregrounds the most consequential shifts shaping stakeholders' choices. It emphasizes practical implications for product development, clinical validation, regulatory strategy, and commercial models, and it identifies where near-term opportunities for differentiation are emerging. The aim is to equip decision-makers with a focused understanding of technology trajectories and operational levers that will determine success in the liquid biopsy ecosystem.

How converging technical advances, multimodal biomarkers, and evolving clinical workflows are rapidly reshaping breast cancer liquid biopsy practice and commercialization

The landscape of breast cancer liquid biopsy is being transformed by a confluence of technical maturation, clinical evidence accumulation, and shifting care paradigms that favor less invasive diagnostics. Advances in assay sensitivity have expanded the clinical envelope, enabling detection of low-frequency variants and minimal residual disease signals that were previously below reliable thresholds. This technical progress has, in turn, unlocked new clinical applications: longitudinal monitoring for recurrence, molecularly informed treatment selection in both advanced and earlier stages, and targeted screening strategies for high-risk cohorts.

Concurrently, integration of multi-analyte approaches and richer biomarker panels is fostering a move away from single-analyte assays toward platforms that combine circulating tumor DNA signals with circulating tumor cells, exosomal content, and protein markers. The integration of orthogonal analytes improves confidence in clinical interpretation and reduces false positives in screening contexts. In parallel, the growing sophistication of bioinformatics, including machine learning-driven signal deconvolution and standardized variant annotation, is reducing inter-laboratory variability and improving clinical utility.

Regulatory and reimbursement ecosystems are also shifting, with payers and guideline committees increasingly recognizing defined use cases where liquid biopsy meaningfully alters patient management. Partnerships between diagnostic developers and clinical networks are accelerating prospective validation and real-world evidence generation. Taken together, these forces create a landscape in which commercial success depends not only on assay performance but on ecosystem fit-laboratory integration, clinician workflow alignment, and clear evidence of clinical benefit.

Assessment of how recent tariff shifts and trade policy adjustments are altering supply chains, procurement strategies, and operational costs in the liquid biopsy ecosystem

Tariff policy developments and cross-border trade measures can exert meaningful pressure on the supply chain for reagents, instruments, and components that underpin liquid biopsy solutions. In 2025, tariff adjustments and trade-related policy shifts have affected costs for imported instrumentation, consumables used in nucleic acid extraction and library preparation, and specialized plastics and microfluidic components. These added import costs have a cascading effect: laboratory operating budgets face higher per-test reagent expenses; instrument vendors and service providers reassess distribution pricing; and procurement teams must re-evaluate sourcing strategies to protect margins.

Beyond direct cost impacts, tariffs influence strategic sourcing decisions and may spur nearshoring of certain manufacturing activities or supply chain diversification. Companies with vertically integrated manufacturing or regional production footprints are better positioned to buffer tariff volatility, while smaller innovators reliant on specialized overseas suppliers may face longer lead times and margin compression. In response, firms are renegotiating supplier contracts, increasing inventory buffers, and pursuing alternative materials or workflow optimizations to maintain assay cost-effectiveness.

Importantly, clinical adoption and policy stakeholders are attentive to any cost-driven shifts in test accessibility. Laboratories and healthcare providers weigh the trade-offs between premium, highly automated platforms and lower-cost manual workflows, especially in health systems under fiscal pressure. Thus, tariff-driven cost dynamics are shaping near-term competitive positioning and prompting strategic responses across procurement, pricing, and manufacturing that will influence which technologies scale and where clinical services expand.

In-depth segmentation analysis that links technology types, biomarker classes, clinical applications, sample matrices, end user profiles, and cancer stage to prioritize development pathways

A nuanced understanding of segmentation reveals how distinct technological pathways and clinical applications create multiple routes to value. Technology segmentation spans BEAMing, digital PCR, next generation sequencing, and qPCR platforms. Within digital PCR there are chip-based and droplet implementations, each optimized for different throughput and sensitivity trade-offs. Next generation sequencing approaches include targeted panels that concentrate on actionable hotspots, whole exome sequencing that expands coverage of coding regions for discovery and broader profiling, and whole genome sequencing that, while more resource-intensive, enables comprehensive genomic interrogation. Quantitative PCR platforms include multiplex quantitative PCR for simultaneous target detection and real-time quantitative PCR for dynamic monitoring applications.

Biomarker type segmentation captures circulating free DNA, circulating tumor cells, circulating tumor DNA, and exosomes, with exosomal analyses split into exosomal protein and exosomal RNA assessments. These analyte distinctions matter clinically: circulating tumor DNA and exosomal RNA are valuable for mutation profiling and non-invasive molecular signatures, while circulating tumor cells provide cellular context that can inform phenotypic and resistance mechanism analyses. Application-driven segmentation differentiates early detection, minimal residual disease, recurrence monitoring, and treatment selection. Early detection itself bifurcates into high-risk screening and population screening, while minimal residual disease focuses on post-treatment surveillance, requiring exceptionally high sensitivity and longitudinal sampling fidelity.

Sample type further conditions assay design and logistics; plasma remains the dominant matrix for DNA-based assays, while serum, saliva, and urine open opportunities for decentralized collection and patient-centric workflows. End users-diagnostic laboratories, hospitals, and research institutes-have distinct operational priorities, regulatory competencies, and purchasing behaviors that determine preferred throughput and reporting formats. Finally, cancer stage segmentation separates advanced stage and early stage disease, with the advanced stage often emphasizing metastatic-disease applications where concordance with tissue genotyping and therapeutic decision support is critical. When these dimensions are considered together, product development and commercialization strategies can be tailored to specific clinical pathways and user needs to maximize clinical impact and adoption.

How distinct regulatory environments, payer behaviors, and clinical networks across major regions are directing adoption pathways and strategic priorities for liquid biopsy solutions

Regional dynamics shape adoption curves and investment priorities, producing differentiated pathways to scale across major geographies. The Americas are characterized by robust clinical research activity, established reimbursement pathways for defined companion diagnostics, and a dense network of academic medical centers enabling rapid prospective validation. As a result, commercial strategies that emphasize clinical utility studies, payer engagement, and partnerships with large laboratory networks are particularly effective in this region.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory frameworks vary and national healthcare systems drive procurement decisions. In several European jurisdictions, centralized assessment of clinical utility and cost-effectiveness influences adoption, encouraging developers to generate real-world evidence and health economic data. Meanwhile, certain markets within this region are investing in digital pathology and molecular diagnostics capacity expansion, creating opportunities for diagnostic providers that can offer integrated solutions adaptable to diverse reimbursement and laboratory infrastructures.

Asia-Pacific demonstrates a combination of rapid clinical adoption in select markets, government-led screening and early detection initiatives, and growing local manufacturing capabilities. Policymakers and healthcare systems in parts of this region are actively implementing population health programs that could incorporate non-invasive screening paradigms. Consequently, strategies that address scalability, affordability, and local regulatory alignment are essential to realize broader uptake across varied healthcare delivery models.

Competitive landscape insights highlighting how platform innovation, evidence partnerships, and service models are determining leadership in the liquid biopsy arena

Competitive activity in the liquid biopsy domain combines platform innovation, strategic partnerships, and ecosystem orchestration. Established diagnostic firms and sequencing specialists continue to refine assay sensitivity and broaden actionable content, while nimble biotech startups focus on niche clinical applications or proprietary biomarkers that promise differentiation. Collaborative arrangements between technology providers and clinical networks accelerate prospective validation studies and support pathway adoption by aligning evidence generation with clinical decision points.

Manufacturers of instrumentation and consumables are pursuing modular approaches that allow laboratories to scale capacity incrementally while preserving analytical performance. At the same time, service-oriented business models-centralized reference testing, subscription analytics, and laboratory-as-a-service offerings-are gaining traction as ways to lower barriers to clinical use and accelerate time to result. Investment patterns reflect a balance between platform-led bets and application-specific assays; portfolio diversification reduces exposure to single-use-case outcomes and supports revenue resilience.

Additionally, companies that integrate robust data analytics, standardized reporting, and clinician-facing interpretive support tools are better positioned to win adoption among hospitals and large diagnostic laboratories. Strategic alliances with contract research organizations and academic centers facilitate translational studies that validate clinical utility and foster guideline inclusion, which in turn strengthens long-term commercial prospects. Leaders will be those that couple technical excellence with pragmatic go-to-market models and evidence-generating partnerships.

Practical and prioritized strategic actions for leaders to enhance assay performance, stabilize supply chains, secure reimbursement, and accelerate clinical adoption in liquid biopsy

Industry leaders should prioritize a set of strategic moves that align scientific capability with operational scalability and payer readiness. First, focus investment on assay sensitivity and specificity that match defined clinical use cases, especially minimal residual disease and early detection in high-risk cohorts, where analytical performance directly influences clinical decision-making. Complement technical development with prospective clinical studies embedded in care pathways to demonstrate actionable impact on treatment choices and patient outcomes.

Second, strengthen supply chain resilience by diversifying component sourcing and evaluating regional manufacturing or assembly options. Such measures reduce exposure to trade-related cost volatility and improve time-to-deployment for clinical sites. Third, design commercial models that reflect end-user workflows: offer flexible laboratory integrations for diagnostic laboratories, turn-key solutions for hospital systems, and research partnerships that lower technical adoption barriers for academic centers. Invest in clinician-facing interpretive tools and reporting standards to reduce cognitive burden and streamline uptake.

Fourth, cultivate payer and health technology assessment engagement early, providing robust real-world evidence and health economic data tailored to regional reimbursement frameworks. Fifth, pursue partnerships across the diagnostic, pharma, and clinical research ecosystem to embed assays in therapeutic development programs and guideline-forming studies. Finally, maintain a disciplined portfolio approach that balances platform investments with targeted assays, enabling both broad capability and focused differentiation in priority clinical niches.

A transparent research framework combining systematic literature review and targeted stakeholder interviews to produce validated, regionally aware strategic insights

The research approach underpinning this analysis combined structured secondary literature synthesis with targeted primary stakeholder engagement to ensure findings reflect current scientific, regulatory, and commercial realities. Secondary research involved systematic review of peer-reviewed clinical studies, regulatory guidance documents, conference proceedings, and open-source technical white papers to map assay performance characteristics, biomarker validation, and evolving clinical guidelines. Emphasis was placed on cross-validating published analytic sensitivity and specificity benchmarks and on understanding contemporary bioinformatics practices for variant calling and interpretation.

Primary research included in-depth interviews with clinical oncologists, laboratory directors, payers, and industry executives to contextualize barriers to adoption, procurement priorities, and evidence expectations. Interviews were conducted with a geographically diverse sample to capture regional differences in regulatory interpretation and healthcare delivery models. Data and insights were triangulated across sources to mitigate single-source bias and to reconcile differences between controlled study outcomes and real-world operational constraints.

Analytical methods included qualitative thematic analysis to distill strategic implications and scenario-based assessment to evaluate supply chain and pricing sensitivities under policy shifts. Limitations are acknowledged: rapidly emerging studies and proprietary commercial developments can change the competitive landscape; therefore, continuous surveillance of scientific literature and regulatory announcements is recommended. Ethical research practices, including informed consent for interviews and confidentiality safeguards for proprietary inputs, were observed throughout the process.

Concluding perspective on aligning analytical innovation, evidence generation, and commercial execution to realize the clinical promise of liquid biopsy in breast cancer care

Liquid biopsy for breast cancer stands at an inflection point where technical capability, clinical need, and commercial incentive are aligning to enable broader clinical utility. The maturation of high-sensitivity assays and multi-analyte approaches increases the likelihood that non-invasive tests will play a substantive role in treatment selection, minimal residual disease monitoring, and stratified screening strategies. At the same time, pragmatic constraints such as supply chain reliability, reimbursement alignment, and laboratory operational integration will determine the pace and scale of adoption.

To capitalize on this moment, organizations must adopt integrated strategies that pair robust analytical performance with evidence generation tailored to clinical decision points and payer expectations. Investment in clinician education, standardization of reporting, and partnerships that embed assays within therapeutic development programs will accelerate acceptance. Regional nuances-differences in regulatory frameworks, reimbursement mechanisms, and healthcare delivery models-require localized approaches rather than one-size-fits-all commercialization plans.

Ultimately, the clinical promise of liquid biopsy will be realized through coordinated action: deliberate technical development, disciplined evidence generation, and adaptive commercial strategies that respond to evolving policy and care delivery landscapes. Stakeholders that move quickly to align these elements will shape the standards of care and capture long-term clinical and commercial value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advances in ultra-sensitive methylation-based ctDNA assays improving minimal residual disease detection in breast cancer
  • 5.2. Expansion of point-of-care liquid biopsy platforms for rapid monitoring of therapy response in metastatic breast cancer
  • 5.3. Collaboration between pharmaceutical and diagnostics companies to co-develop companion liquid biopsy tests for targeted therapies
  • 5.4. Emergence of exosome-based liquid biopsy tests offering comprehensive biomarker profiling and drug resistance insights
  • 5.5. Regulatory approvals of FDA-designated breakthrough breast cancer liquid biopsy tests accelerating commercial adoption
  • 5.6. Development of standardized preanalytical workflows to reduce variability in sample collection and ctDNA analysis
  • 5.7. Increasing reimbursement coverage and health economic evidence supporting routine liquid biopsy use in clinical practice
  • 5.8. Integration of multi-omics approaches combining ctDNA, exosome RNA, and protein markers for holistic disease monitoring

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Breast Cancer Liquid Biopsy Market, by Technology

  • 8.1. BEAMing
  • 8.2. Digital PCR
    • 8.2.1. Chip Based Digital PCR
    • 8.2.2. Droplet Digital PCR
  • 8.3. Next Generation Sequencing
    • 8.3.1. Targeted Sequencing
    • 8.3.2. Whole Exome Sequencing
    • 8.3.3. Whole Genome Sequencing
  • 8.4. qPCR
    • 8.4.1. Multiplex Quantitative PCR
    • 8.4.2. Real Time Quantitative PCR

9. Breast Cancer Liquid Biopsy Market, by Biomarker Type

  • 9.1. Circulating Free DNA
  • 9.2. Circulating Tumor Cells
  • 9.3. Circulating Tumor DNA
  • 9.4. Exosomes
    • 9.4.1. Exosomal Protein
    • 9.4.2. Exosomal RNA

10. Breast Cancer Liquid Biopsy Market, by Application

  • 10.1. Early Detection
    • 10.1.1. High Risk Screening
    • 10.1.2. Population Screening
  • 10.2. Minimal Residual Disease
    • 10.2.1. Post Treatment Surveillance
  • 10.3. Recurrence Monitoring
  • 10.4. Treatment Selection

11. Breast Cancer Liquid Biopsy Market, by Sample Type

  • 11.1. Plasma
  • 11.2. Saliva
  • 11.3. Serum
  • 11.4. Urine

12. Breast Cancer Liquid Biopsy Market, by End User

  • 12.1. Diagnostic Laboratories
  • 12.2. Hospitals
  • 12.3. Research Institutes

13. Breast Cancer Liquid Biopsy Market, by Cancer Stage

  • 13.1. Advanced Stage
    • 13.1.1. Metastatic Disease
  • 13.2. Early Stage

14. Breast Cancer Liquid Biopsy Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Breast Cancer Liquid Biopsy Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Breast Cancer Liquid Biopsy Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Roche Diagnostics International AG
    • 17.3.2. Guardant Health, Inc.
    • 17.3.3. Natera, Inc.
    • 17.3.4. Illumina, Inc.
    • 17.3.5. Thermo Fisher Scientific Inc.
    • 17.3.6. Exact Sciences Corporation
    • 17.3.7. Sysmex Inostics GmbH
    • 17.3.8. Qiagen N.V.
    • 17.3.9. Bio-Rad Laboratories, Inc.
    • 17.3.10. Biocept, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BREAST CANCER LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. BREAST CANCER LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BREAST CANCER LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MULTIPLEX QUANTITATIVE PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MULTIPLEX QUANTITATIVE PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MULTIPLEX QUANTITATIVE PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MULTIPLEX QUANTITATIVE PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MULTIPLEX QUANTITATIVE PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MULTIPLEX QUANTITATIVE PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REAL TIME QUANTITATIVE PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REAL TIME QUANTITATIVE PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REAL TIME QUANTITATIVE PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REAL TIME QUANTITATIVE PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REAL TIME QUANTITATIVE PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REAL TIME QUANTITATIVE PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING FREE DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING FREE DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING FREE DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING FREE DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING FREE DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING FREE DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL PROTEIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL PROTEIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL PROTEIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL PROTEIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL PROTEIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL PROTEIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL RNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL RNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL RNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL RNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL RNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL RNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HIGH RISK SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HIGH RISK SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HIGH RISK SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HIGH RISK SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HIGH RISK SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HIGH RISK SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POPULATION SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POPULATION SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POPULATION SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POPULATION SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POPULATION SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POPULATION SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST TREATMENT SURVEILLANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST TREATMENT SURVEILLANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST TREATMENT SURVEILLANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST TREATMENT SURVEILLANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST TREATMENT SURVEILLANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST TREATMENT SURVEILLANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY METASTATIC DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY METASTATIC DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY METASTATIC DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY METASTATIC DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY METASTATIC DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY METASTATIC DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY STAGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY STAGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY STAGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-20